Recurrence in Patients With Differentiated Thyroid Cancer

Launched by ASSIUT UNIVERSITY · Nov 30, 2023

Keywords

ClinConnect Summary

This clinical trial is studying patients with differentiated thyroid cancer (DTC) to understand how often the cancer comes back after treatment. Specifically, the researchers want to find out how the amount of radioactive iodine (RAI) given after surgery affects the chances of staying cancer-free. Participants in the study will be those who have had their thyroid gland removed (surgery) and have received RAI treatment, along with certain tests to check their health.

To be eligible for this study, patients must have had their entire or part of their thyroid removed and should not have any distant spread of cancer. They should also have had a whole body scan after RAI and specific health tests. Unfortunately, those who missed follow-up appointments or lack surgical details won’t be included. The trial is not yet recruiting participants, but once it starts, those who qualify will help doctors learn more about managing DTC and improving care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with DTC (differentiated thyroid cancer) who underwent total or subtotal thyroidectomy without distant metastasis and gross residual tumors.
• • Followed by ablation with RAI and underwent post RAI whole body scan.
• • Having baseline TG (thyroglobulin), Anti-TG antibodies (anti thyroglobulin) and neck US.
• • Patients with lymph node metastasis will be included if their lymph nodes had been dissected and no unresectable disease remained.
• Exclusion Criteria:
• • Patients who received RAI and missed follow-up.
• • Patients with no surgical or pathological data.